Page 50 - BH-2-4
P. 50
Brain & Heart Transforming transthyretin cardiac amyloidosis
18. Hartling L, Hamm M, Milne A, et al. Validity and Inter- 2019;6(6):1128-1139.
rater Reliability Testing of Quality Assessment Instruments; doi: 10.1002/ehf2.12518
2012. Available: https://www.ahrq.gov [Last accessed on
2024 Jul 15]. 21. Maurer MS, Grogan DR, Judge DP, et al. Tafamidis
in transthyretin amyloid cardiomyopathy: Effects on
19. Rapezzi C, Elliott P, Damy T, et al. Efficacy of tafamidis
in patients with hereditary and wild-type transthyretin transthyretin stabilization and clinical outcomes. Circ Heart
amyloid cardiomyopathy: Further analyses from ATTR- Fail. 2015;8(3):519-526.
ACT. JACC Heart Fail. 2021;9(2):115-123. doi: 10.1161/CIRCHEARTFAILURE.113.000890
doi: 10.1016/j.jchf.2020.09.011 22. Stern LK, Patel J. Cardiac amyloidosis treatment. Methodist
Debakey Cardiovasc J. 2022;18(2):59-72.
20. Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis:
An update on diagnosis and treatment. ESC Heart Failure. doi: 10.14797/mdcvj.1050
Volume 2 Issue 4 (2024) 10 doi: 10.36922/bh.4250
